Amakem Appoints Kieran Rooney as Vice President, Business Development

    Amakem Appoints Kieran Rooney as Vice President, Business Development

  PR Newswire

  DIEPENBEEK, Belgium, June 24, 2013

DIEPENBEEK, Belgium, June 24, 2013 /PRNewswire/ --

Amakem NV, a clinical stage ophthalmology company, today announces that it has
appointed Dr. Kieran Rooney as Vice President, Business Development.

Dr. Rooney brings to Amakem over 25 years of experience in the biotech and
pharma industries and a proven track record in business development,
commercial management and strategic consulting. As Founder and Managing
Director of Halo BioConsulting, Dr. Rooney has worked extensively in the
ophthalmology space, supporting companies in both Europe and the US on
transactions and commercial strategy.

Dr. Rooney was previously a Consultant to the UK Government, focusing on the
provision of commercial consulting, business development and global
deal-making services to UK-based life sciences companies. Prior to his work
for the UK Government, Dr. Rooney held Business Development Director roles at
companies including Smith & Nephew PLC, F2G Limited, Pharsight Corporation,
and MDS Pharma Services.

Dr. Jack Elands, CEO of Amakem, said: "It is a great pleasure to welcome
Kieran to our management team at Amakem. He has been involved in multiple
deals in the ophthalmology area and his broad-ranging experience in business
development will be invaluable as we continue to deliver value from our unique
kinase technology platform in ophthalmology. Our lead asset, AMA0076, is
progressing through clinical development and we look forward to announcing top
line results of our Phase 2a study in glaucoma later this year."

Dr. Rooney holds a BSc in Pharmacy from University of Sunderland, UK and a PhD
in Neuropharmacology from University of Wales, Cardiff, UK.

About Amakem

Amakem is an ophthalmology company developing new treatments for serious eye
conditions. Amakem's product pipeline is based on its unique Localized Drug
Action platform which is designed to generate safe and effective novel kinase
inhibitors that minimize

systemic exposure with the aim of reducing side effects. Amakem's lead
candidate, AMA0076, is for glaucoma and entered Phase 2a development late last
year. The Company is also working to apply the Localized Drug Action approach
to a range of other eye diseases.

Founded in 2010, Amakem has raised more than €21m in funding and is backed by
leading life sciences investors including Forbion, Omnes Capital (previously
Crédit Agricole), Vesalius BioCapital, LRM, PMV/Vinnof and Life Science
Research Partners.

Amakem is based in Belgium and located in the life sciences incubator
"BioVille" at the University of Hasselt. The Company has a long-standing
collaboration with the Ophthalmology Research Center of the University Leuven
Hospital, where it sponsors a Chair in Ophthalmology Translational Research.

For more information, please contact Amakem NV Jack Elands, CEO +32(0)474-828-580 Citigate Dewe Rogerson Chris
Gardner/Nina Enegren +44(0)20-7638-9571
Press spacebar to pause and continue. Press esc to stop.